Influenza, Human: all 2,265 studies

Page 9 of 23. Open to participants first (174), then studies with results posted, then the rest; newest registration first within each.

• Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza VaccineCompletedNCT00521586Phase 3Results posted
• Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008CompletedNCT00511914Phase 3Results posted
• Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in AdultsCompletedNCT00510874Phase 1Results posted
• Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed AdultsCompletedNCT00506350Phase 2Results posted
• Intradermal Influenza Vaccine Study in EldersCompletedNCT00504231Phase 2Results posted
• Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in ChildrenCompletedNCT00502593Phase 2Results posted
• Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and ElderlyCompletedNCT00492063Phase 3Results posted
• Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult SubjectsCompletedNCT00481065Phase 2Results posted
• Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years OldCompletedNCT00464672Phase 3Results posted
• A Phase 2 Study to Evaluate Immune Responses of FluMist®CompletedNCT00461981Phase 2Results posted
• Study of Long-term Antibody Persistence After a Booster Dose of Menitorix VaccineCompletedNCT00454987Phase 4Results posted
• Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening InfluenzaCompletedNCT00453999Phase 2Results posted
• Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in AdultsCompletedNCT00449670Phase 3Results posted
• Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)CompletedNCT00441012Phase 3Results posted
• Higher Dose Intradermal H5 VaccineCompletedNCT00439335Phase 1/2Results posted
• Interferon as a Mucosal Adjuvant for Influenza Vaccine Given IntranasallyCompletedNCT00436046Phase 1Results posted
• Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)CompletedNCT00430521Phase 2Results posted
• Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.CompletedNCT00419263Phase 2Results posted
• A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised ParticipantsCompletedNCT00412737Phase 4Results posted
• Open-Label Study of H5 Vaccine in Participants of Protocol 04-077CompletedNCT00402649Phase 1/2Results posted
• Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of AgeCompletedNCT00397215Phase 2Results posted
• Oseltamivir Treatment for Children Less Than 24 Months of Age With InfluenzaCompletedNCT00391768Phase 1/2Results posted
• Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and ChildrenCompletedNCT00391391Phase 2Results posted
• Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the ElderlyCompletedNCT00391053Phase 3Results posted
• Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.CompletedNCT00390884Phase 4Results posted
• Trial to Collect Safety Data and Sera for Immunogenicity TestingCompletedNCT00389857Phase 4Results posted
• Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® VaccineCompletedNCT00389532Phase 4Results posted
• Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly SubjectsCompletedNCT00388583Phase 2Results posted
• Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine CandidateCompletedNCT00385840Phase 2Results posted
• Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in ChildrenCompletedNCT00383123Phase 3Results posted
• Development of Immune Globulin Treatment for Avian FluTerminatedNCT00383071Phase 2Results posted
• Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™CompletedNCT00377611Phase 4Results posted
• Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine CandidateCompletedNCT00374842Phase 2Results posted
• Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine CandidateCompletedNCT00363077Phase 2Results posted
• Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of AgeCompletedNCT00345579Phase 3Results posted
• Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine CandidateCompletedNCT00321763Phase 2Results posted
• Study to Evaluate an Influenza Vaccine CandidateCompletedNCT00321373Phase 2Results posted
• Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and AboveCompletedNCT00319098Phase 3Results posted
• Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly PopulationCompletedNCT00318149Phase 2Results posted
• Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)CompletedNCT00310804Phase 3Results posted
• Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly PopulationCompletedNCT00306995Phase 2Results posted
• Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and ElderlyCompletedNCT00306527Phase 3Results posted
• High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian InfluenzaCompletedNCT00298233Phase 2Results posted
• Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate VaccineCompletedNCT00289783Phase 3Results posted
• Comparison of Full-dose Flu Vaccine to Half-dose Flu VaccineCompletedNCT00283283Phase 2Results posted
• Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy AdultsCompletedNCT00264576Phase 2Results posted
• Safety and Immunogenicity of the 2005-2006 Fluzone® VaccineCompletedNCT00258830Phase 4Results posted
• Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone VaccineCompletedNCT00258817Phase 4Results posted
• Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in ChildrenCompletedNCT00228917Phase 3Results posted
• Control of Epidemic Influenza Through a School-based Influenza Vaccination ProgramCompletedNCT00138294Phase 4Results posted
• Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30mCompletedNCT00136604Phase 3Results posted
• 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of AgeCompletedNCT00129116Phase 2Results posted
• Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) VaccineCompletedNCT00127855Phase 2Results posted
• A Study to Evaluate the Immune Responses of Subunit Influenza Vaccine in Healthy AdultsActive, not recruitingNCT07854392Phase 4
• RSV, Influenza, and SARS-CoV-2 Outcomes in Severely Immunosuppressed AdultsActive, not recruitingNCT07816471
• Comparative Immunologic Mechanisms and Microbiome Interactions Following Different Influenza Vaccine Formulations in Older AdultsCompletedNCT07805837Phase 4
• Rule-Based High-Risk FluCompletedNCT07798882Not applicable
• Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose)CompletedNCT07737106Phase 1
• Preliminary Safety Assessment of a Quadrivalent Subunit Influenza Vaccine in ChinaCompletedNCT07710586Phase 4
• Respiratory Pathogen Distribution During and After the COVID-19 PandemicCompletedNCT07601126
• Communication Intervention to Improve Influenza Vaccination Rates Among Elderly in Can ThoCompletedNCT07508189Not applicable
• Post-exposure Influenza Prophylaxis in a Hospital SettingActive, not recruitingNCT07496736Phase 3
• A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsActive, not recruitingNCT07496450Phase 3
• Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderActive, not recruitingNCT07421050Phase 1
• Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderActive, not recruitingNCT07421037Phase 1
• Lower Respiratory Tract Infections Managed in Primary Care in FranceCompletedNCT07416266
• Kaiser Colorado Flu NudgeActive, not recruitingNCT07372950Not applicable
• This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate InfluenzaActive, not recruitingNCT07371650Phase 2
• H1ssF Flu Vaccine Clinical TrialWithdrawnNCT07340047Phase 1
• Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and OlderCompletedNCT07332689
• A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)Active, not recruitingNCT07300085Phase 1
• Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza VaccineActive, not recruitingNCT07291635Phase 1/2
• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) StudyActive, not recruitingNCT07287137Phase 4
• Effectiveness of Ammonium Chloride in Reducing Viral LoadCompletedNCT07254052
• The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) StudyActive, not recruitingNCT07240922Phase 4
• Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)Active, not recruitingNCT07240558Phase 3
• Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated VaccineActive, not recruitingNCT07232745Phase 4
• Influenza Vaccination Against Infectious Complications and Mortality in Older Adults With Fractures: a Large-scale Retrospective Cohort StudyCompletedNCT07231016
• A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)Active, not recruitingNCT07225959Phase 2
• Strengthening IntentionsActive, not recruitingNCT07222774Not applicable
• Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant WomenCompletedNCT07211152Phase 3
• A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and AboveCompletedNCT07204964Phase 2
• Vaccination Nudges From PharmacistsActive, not recruitingNCT07161739Not applicable
• A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and OlderCompletedNCT07121192Phase 2
• Pilot Influenza Challenge StudyActive, not recruitingNCT07063849Phase 1
• A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy AdultsCompletedNCT07019883Phase 1
• Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)CompletedNCT06987942Phase 4
• Human Infection Study of H3N2 Influenza in Healthy AdultsCompletedNCT06972810Not applicable
• A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of AgeCompletedNCT06864143Phase 2
• A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.CompletedNCT06850051Phase 1
• Digital Health Intervention On Awareness Of Vaccination Against Influenza Among Adults With DiabetesCompletedNCT06840236
• Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune ResponsesActive, not recruitingNCT06824779Phase 4
• A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy PeopleCompletedNCT06821061Phase 1/2
• Flu Infection at UPHSCompletedNCT06807840
• Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German ParticipantsCompletedNCT06800885
• A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like IllnessCompletedNCT06779981
• A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection QuestionnaireCompletedNCT06765187
• A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and OlderCompletedNCT06744205Phase 1/2
• Comparison Between Different Sampling Sites for Detection of Respiratory VirusesCompletedNCT06743750
• Influenza Vaccine Elicited Immune Response in Immunocompromised PatientsCompletedNCT06738082

← Influenza, Human overview